Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03052517
Other study ID # CQAW039A2315
Secondary ID 2016-001560-11
Status Terminated
Phase Phase 3
First received
Last updated
Start date March 21, 2017
Est. completion date March 16, 2020

Study information

Verified date September 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when added to the Global Initiative for Asthma (GINA) steps 3, 4, and 5 standard-of-care (SoC) asthma therapy (GINA 2016), in patients with moderate-to- severe asthma.

The purpose of this study was to provide long-term safety data for QAW039 150 mg once daily and 450 mg once daily, compared with placebo, when added to GINA steps 3, 4, and 5 standard-of-care asthma therapy (GINA 2020) in adult and adolescent (≥12 years) patients with moderate-to-severe asthma. The study included 2 cohorts of patients:

1. Rollover patients who had completed any of the four Phase 3 pivotal efficacy studies with QAW039 (QAW039A2307, QAW039A2314, QAW039A2316, or QAW039A2317, hereafter referred to as Studies A2307, A2314, A2316, and A2317), thus providing data for a longer duration of exposure, and

2. New patients who had not previously participated in a study of QAW039, permitting an increase in the number of patients with long-term exposure to QAW039.

By including these 2 categories of patients, the total number of patients treated with QAW039 as well as the duration of exposure to QAW039 treatment was substantially increased, supporting evaluation of the safety profile of QAW039.


Description:

The study comprised 2-treatment period. Treatment Period 1 was a 52-week, double-blind treatment period in which QAW039 450 mg or 150 mg or placebo was added to standard-of-care asthma therapy according to GINA guidelines. Treatment Period 2 was an optional 104-week, single-blind treatment period in which patients received QAW039 450 mg or 150 mg or placebo added to standard-of-care asthma therapy according to GINA guidelines.


Recruitment information / eligibility

Status Terminated
Enrollment 2538
Est. completion date March 16, 2020
Est. primary completion date February 19, 2020
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria:

Patients completing a prior Phase 3 study of QAW039:

- Informed consent and assent (if applicable).

- Completion of the Treatment Period (on blinded study drug) of a prior Phase 3 study of QAW039.

- Patient is able to safely continue into the study as judged by the investigator.

Patients who have not previously participated in a study of QAW039:

- Written informed consent.

- A diagnosis of asthma,uncontrolled on GINA 3/4/5 asthma medication.

- Evidence of airway reversibility or airway hyper- reactivity.

- FEV1 of =85% of the predicted normal value.

- An ACQ score =1.5 prior to entering the study.

Exclusion Criteria:

Patients completing a prior phase 3 study of QAW039:

- Pregnant or nursing (lactating) women.

- Women of child-bearing potential unless they are using basic methods of contraception during dosing of study drug

- Patients who did not complete the Treatment Period on blinded study drug of the prior QAW039 study they participated in.

- Inability to comply with all study requirements.

- Patient who experienced a serious and drug-related AE in the prior QAW039 study they participated in.

Patients who have not previously participated in a study of QAW039:

- Use of other investigational drugs within 5 half-lives of study entry, or within 30 days, whichever is longer.

- Subjects who have participated in another trial of QAW039 (i.e.-the patient was randomized in another study).

- A QTcF (Fridericia) =450 msec (male) or =460 msec (female).

- History of malignancy with the exception of local basal cell carcinoma of the skin

- Pregnant or nursing (lactating) women.

- Serious co-morbidities.

- Patients on greater than 20 mg of simvastatin> 40 mg of atorvastatin, >40 mg of pravastatin, or >2 mg of pitavastatin. Statin doses less than or equal to these doses as well as other statins will be permitted during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
QAW039 150 mg
One tablet of QAW039 150 mg once daily
QAW039 450 mg
One tablet of QAW039 450 mg once daily
Placebo
One tablet of Placebo once daily

Locations

Country Name City State
Argentina Novartis Investigative Site Berazategui Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Lanus Buenos Aires
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Mendoza
Argentina Novartis Investigative Site Mendoza
Argentina Novartis Investigative Site Ranelagh, Partido De Berazate Buenos Aires
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Salta
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site Santa Fe Rosario
Argentina Novartis Investigative Site Santa Fe
Argentina Novartis Investigative Site Santa Rosa La Pampa
Australia Novartis Investigative Site Clayton Victoria
Australia Novartis Investigative Site Footscray Victoria
Australia Novartis Investigative Site Melbourne Victoria
Austria Novartis Investigative Site Feldkirch
Austria Novartis Investigative Site Vienna
Austria Novartis Investigative Site Wien
Belgium Novartis Investigative Site Aalst
Belgium Novartis Investigative Site Brussel
Belgium Novartis Investigative Site Bruxelles
Belgium Novartis Investigative Site Eghezee
Belgium Novartis Investigative Site Erpent
Belgium Novartis Investigative Site Herentals
Belgium Novartis Investigative Site Kortrijk
Belgium Novartis Investigative Site Liege
Brazil Novartis Investigative Site Blumenau Santa Catarina
Brazil Novartis Investigative Site Goiania GO
Brazil Novartis Investigative Site Porto Alegre Porto Alegre RS
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Rio de Janeiro RJ
Brazil Novartis Investigative Site Sao Bernardo do Campo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sorocaba SP
Bulgaria Novartis Investigative Site Pleven
Bulgaria Novartis Investigative Site Ruse
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Stara Zagora
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Vancouver British Columbia
Canada Novartis Investigative Site Vancouver
Canada Novartis Investigative Site Windsor Ontario
China Novartis Investigative Site Beijing
China Novartis Investigative Site Chang Chun Jilin
China Novartis Investigative Site Chengdu Sichuan
China Novartis Investigative Site Chongqing
China Novartis Investigative Site Guang Zhou Guang Dong Province
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shijiazhuang Hebei
China Novartis Investigative Site Xian Shanxi
Colombia Novartis Investigative Site Bogota
Colombia Novartis Investigative Site Bucaramanga
Colombia Novartis Investigative Site Ibague Tolima
Czechia Novartis Investigative Site Brno
Czechia Novartis Investigative Site Jindrichuv Hradec Czech Republic
Czechia Novartis Investigative Site Karlovy Vary
Czechia Novartis Investigative Site Mlada Boleslav
Czechia Novartis Investigative Site Teplice Czech Republic
Czechia Novartis Investigative Site Teplice CZE
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tartu
Finland Novartis Investigative Site Helsinki
France Novartis Investigative Site Dijon
France Novartis Investigative Site Le Kremlin Bicetre
France Novartis Investigative Site Lyon Cedex 04
France Novartis Investigative Site Marseille
France Novartis Investigative Site Montpellier cedex 5 Herault
France Novartis Investigative Site Nantes
France Novartis Investigative Site Paris cedex 18
France Novartis Investigative Site Strasbourg Cedex
Germany Novartis Investigative Site Aschaffenburg
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Cottbus Sachsen
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Landsberg
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Witten
Greece Novartis Investigative Site Athens GR
Greece Novartis Investigative Site Athens GR
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Thessaloniki GR
Guatemala Novartis Investigative Site Gautemala City Gautemala
Guatemala Novartis Investigative Site Guatemala City GTM
Guatemala Novartis Investigative Site Guatemala City GTM
Guatemala Novartis Investigative Site Guatemala City
Guatemala Novartis Investigative Site Guatemala City
Hungary Novartis Investigative Site Budaors HUN
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Godollo
Hungary Novartis Investigative Site Gyor HUN
Hungary Novartis Investigative Site Hajdunanas HUN
Hungary Novartis Investigative Site Komarom
Hungary Novartis Investigative Site Mako
Hungary Novartis Investigative Site Pecs
Hungary Novartis Investigative Site Puspokladany HUN
Hungary Novartis Investigative Site Siofok
Hungary Novartis Investigative Site Szazhalombatta HUN
Hungary Novartis Investigative Site Szeged
Hungary Novartis Investigative Site Torokbalint
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Bikaner Rajasthan
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site DehraDun Uttarakhand
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Vadodara Gujarat
Israel Novartis Investigative Site Ashkelon
Israel Novartis Investigative Site Haifa
Israel Novartis Investigative Site Haifa
Israel Novartis Investigative Site Jerusalem
Israel Novartis Investigative Site Jerusalem
Israel Novartis Investigative Site Petach Tikva
Israel Novartis Investigative Site Rehovot
Japan Novartis Investigative Site Chikushino-city Fukuoka
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Chuo-ku Tokyo
Japan Novartis Investigative Site Chuo-ku Tokyo
Japan Novartis Investigative Site Fukuoka city Fukuoka
Japan Novartis Investigative Site Habikino city Osaka
Japan Novartis Investigative Site Hamamatsu-city Shizuoka
Japan Novartis Investigative Site Himeji-city Hyogo
Japan Novartis Investigative Site Hiroshima-city Hiroshima
Japan Novartis Investigative Site Iizuka-city Fukuoka
Japan Novartis Investigative Site Itabashi-ku Tokyo
Japan Novartis Investigative Site Kagoshima city Kagoshima
Japan Novartis Investigative Site Kashihara city Nara
Japan Novartis Investigative Site Kasuga-city Fukuoka
Japan Novartis Investigative Site Kishiwada-city Osaka
Japan Novartis Investigative Site Kiyose-city Tokyo
Japan Novartis Investigative Site Koga city Fukuoka
Japan Novartis Investigative Site Koshi-city Kumamoto
Japan Novartis Investigative Site Matsusaka-city Mie
Japan Novartis Investigative Site Matsuyama-city Ehime
Japan Novartis Investigative Site Matsuyama-city Ehime
Japan Novartis Investigative Site Mizunami-city Gifu
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Naka-gun Ibaraki
Japan Novartis Investigative Site Ota-ku Tokyo
Japan Novartis Investigative Site Sagamihara-city Kanagawa
Japan Novartis Investigative Site Sagamihara-city Kanagawa
Japan Novartis Investigative Site Sakaide Kagawa
Japan Novartis Investigative Site Sapporo Hokkaido
Japan Novartis Investigative Site Sapporo Hokkaido
Japan Novartis Investigative Site Sendai-city Miyagi
Japan Novartis Investigative Site Sendai-city Miyagi
Japan Novartis Investigative Site Setagaya-Ku Tokyo
Japan Novartis Investigative Site Setagaya-ku Tokyo
Japan Novartis Investigative Site Shinagawa-ku Tokyo
Japan Novartis Investigative Site Shinjuku ku Tokyo
Japan Novartis Investigative Site Shinjuku-ku Tokyo
Japan Novartis Investigative Site Takamatsu-city Kagawa
Japan Novartis Investigative Site Tokyo Shibuya Ku
Japan Novartis Investigative Site Toshima ku Tokyo
Japan Novartis Investigative Site Tsu-city Mie
Japan Novartis Investigative Site Yanagawa-city Fukuoka
Japan Novartis Investigative Site Yokohama Kanagawa
Japan Novartis Investigative Site Yokohama city Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa
Latvia Novartis Investigative Site Daugavpils
Latvia Novartis Investigative Site Riga
Lebanon Novartis Investigative Site Ashrafieh
Lebanon Novartis Investigative Site Beirut
Lebanon Novartis Investigative Site El Chouf LBN
Lithuania Novartis Investigative Site Kaunas LTU
Lithuania Novartis Investigative Site Kaunas LT
Lithuania Novartis Investigative Site Kaunas LT
Lithuania Novartis Investigative Site Klaipeda
Lithuania Novartis Investigative Site Vilnius
Lithuania Novartis Investigative Site Vilnius LTU
Malaysia Novartis Investigative Site Kota Bharu Kelantan
Malaysia Novartis Investigative Site Kuantan Pahang
Malaysia Novartis Investigative Site Taiping Perak
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Guadalajara Jalisco Jalisco
Mexico Novartis Investigative Site Rio De Janeiro
Netherlands Novartis Investigative Site Arnhem
Netherlands Novartis Investigative Site Leeuwarden
Peru Novartis Investigative Site Cercado De Lima Lima
Peru Novartis Investigative Site Cusco
Peru Novartis Investigative Site Lima
Peru Novartis Investigative Site Piura
Peru Novartis Investigative Site San Isidro Lima
Peru Novartis Investigative Site San Martin de Porres Lima
Philippines Novartis Investigative Site Bulacan
Philippines Novartis Investigative Site Iloilo City
Philippines Novartis Investigative Site Lipa City Batangas
Philippines Novartis Investigative Site Manila
Philippines Novartis Investigative Site Quezon City
Philippines Novartis Investigative Site Quezon City Manila
Poland Novartis Investigative Site Bialystok
Poland Novartis Investigative Site Kielce
Poland Novartis Investigative Site Poznan
Poland Novartis Investigative Site Poznan
Poland Novartis Investigative Site Poznan
Poland Novartis Investigative Site Strzelce Opolskie
Puerto Rico Novartis Investigative Site San Juan
Romania Novartis Investigative Site Bragadiru
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Bucharest District 3
Romania Novartis Investigative Site Cluj Napoca
Romania Novartis Investigative Site Cluj-Napoca
Romania Novartis Investigative Site Constanta ROM
Romania Novartis Investigative Site Deva
Romania Novartis Investigative Site Timisoara Timis
Russian Federation Novartis Investigative Site Barnaul
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Izhevsk
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Nizhnii Novgorod
Russian Federation Novartis Investigative Site Penza
Russian Federation Novartis Investigative Site Perm
Russian Federation Novartis Investigative Site Ryazan
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint-Petersburg
Russian Federation Novartis Investigative Site Sestroretsk
Russian Federation Novartis Investigative Site Smolensk
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site Stavropol
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yekaterinburg
Saudi Arabia Novartis Investigative Site Jeddah
Serbia Novartis Investigative Site Belgrade
Serbia Novartis Investigative Site Belgrade
Serbia Novartis Investigative Site Kragujevac
Serbia Novartis Investigative Site Nis
Serbia Novartis Investigative Site Sremska Kamenica
Singapore Novartis Investigative Site Singapore
Singapore Novartis Investigative Site Singapore
Slovakia Novartis Investigative Site Bardejov Slovak Republic
Slovakia Novartis Investigative Site Bojnice Slovak Republic
Slovakia Novartis Investigative Site Kezmarok
Slovakia Novartis Investigative Site Komarno
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Levice
Slovakia Novartis Investigative Site Levice
Slovakia Novartis Investigative Site Poprad
Slovakia Novartis Investigative Site Presov
Slovakia Novartis Investigative Site Spisska Nova Ves
Slovakia Novartis Investigative Site Zilina
Spain Novartis Investigative Site Barcelona Vic
Spain Novartis Investigative Site Barcelona
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Girona
Spain Novartis Investigative Site Guadalajara
Spain Novartis Investigative Site Jerez Cadiz
Spain Novartis Investigative Site Laredo Cantabria
Spain Novartis Investigative Site Lugo Galicia
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Malaga Andalucia
Spain Novartis Investigative Site Malaga Andalucia
Spain Novartis Investigative Site Marbella Andalucia
Spain Novartis Investigative Site Palma de Mallorca Islas Baleares
Spain Novartis Investigative Site Santiago de Compostela
Spain Novartis Investigative Site Zaragoza
Switzerland Novartis Investigative Site Liestal
Switzerland Novartis Investigative Site Lugano
Taiwan Novartis Investigative Site Taichung
Turkey Novartis Investigative Site Adana
Turkey Novartis Investigative Site Ankara
Turkey Novartis Investigative Site Bursa
Turkey Novartis Investigative Site Istanbul TUR
Turkey Novartis Investigative Site Mersin
Turkey Novartis Investigative Site Yenisehir/Izmir
United Kingdom Novartis Investigative Site Bradford West Yorkshire
United Kingdom Novartis Investigative Site Cambridge Cambrigdeshire
United Kingdom Novartis Investigative Site Chertsey Surrey
United Kingdom Novartis Investigative Site East Yorkshire
United Kingdom Novartis Investigative Site Leicester
United Kingdom Novartis Investigative Site Plymouth Devon
United States Novartis Investigative Site Altoona Pennsylvania
United States Novartis Investigative Site Asheville North Carolina
United States Novartis Investigative Site Bangor Maine
United States Novartis Investigative Site Bellevue Nebraska
United States Novartis Investigative Site Bellingham Washington
United States Novartis Investigative Site Birmingham Alabama
United States Novartis Investigative Site Boerne Texas
United States Novartis Investigative Site Bronx New York
United States Novartis Investigative Site Colorado Springs Colorado
United States Novartis Investigative Site Columbia Maryland
United States Novartis Investigative Site Columbus Ohio
United States Novartis Investigative Site Denver Colorado
United States Novartis Investigative Site East Providence Rhode Island
United States Novartis Investigative Site Edmond Oklahoma
United States Novartis Investigative Site Encinitas California
United States Novartis Investigative Site Fort Worth Texas
United States Novartis Investigative Site Gastonia North Carolina
United States Novartis Investigative Site La Vista Nebraska
United States Novartis Investigative Site Lafayette Colorado
United States Novartis Investigative Site Louisville Kentucky
United States Novartis Investigative Site Marietta Georgia
United States Novartis Investigative Site McKinney Texas
United States Novartis Investigative Site Medford Oregon
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Missoula Montana
United States Novartis Investigative Site Newport Beach California
United States Novartis Investigative Site Oklahoma City Oklahoma
United States Novartis Investigative Site Omaha Nebraska
United States Novartis Investigative Site Omaha Nebraska
United States Novartis Investigative Site Orange California
United States Novartis Investigative Site Overland Park Kansas
United States Novartis Investigative Site Pittsburgh Pennsylvania
United States Novartis Investigative Site Pittsburgh Pennsylvania
United States Novartis Investigative Site Plano Texas
United States Novartis Investigative Site Richmond Virginia
United States Novartis Investigative Site San Antonio Texas
United States Novartis Investigative Site San Diego California
United States Novartis Investigative Site Spokane Washington
United States Novartis Investigative Site Stockton California
United States Novartis Investigative Site Tamarac Florida
United States Novartis Investigative Site Waldorf Maryland
United States Novartis Investigative Site Walnut Creek California
United States Novartis Investigative Site Westminster California
United States Novartis Investigative Site Winter Park Florida
United States Novartis Investigative Site Ypsilanti Michigan
United States Novartis Investigative Site Zachary Louisiana

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Bulgaria,  Canada,  China,  Colombia,  Czechia,  Estonia,  Finland,  France,  Germany,  Greece,  Guatemala,  Hungary,  India,  Israel,  Japan,  Latvia,  Lebanon,  Lithuania,  Malaysia,  Mexico,  Netherlands,  Peru,  Philippines,  Poland,  Puerto Rico,  Romania,  Russian Federation,  Saudi Arabia,  Serbia,  Singapore,  Slovakia,  Spain,  Switzerland,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment Emergent Adverse Events (AEs) up to Week 52 - Cox Regression Model Adverse events starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) were classified as treatment emergent AEs. For this Outcome Measure, AE up to week 52 are reported. 52 weeks
Primary Number of Participants With Treatment Emergent Adverse Events (AEs) up to Week 156 - Cox Regression Model Adverse events starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) were classified as treatment emergent AEs 156 weeks
Primary Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) up to Week 52 - Cox Regression Model Serious Adverse events starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +30 days were classified as treatment emergent SAEs. For this Outcome Measure, AE up to week 52 are reported. 52 weeks
Primary Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) up to Week 156 - Cox Regression Model Serious Adverse events starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +30 days were classified as treatment emergent SAEs. 156 weeks
Primary Number of Participants With Treatment Emergent AEs Leading to Discontinuation From Study Treatment up to Week 52 - Cox Regression Model Adverse events leading to study treatment discontinuation starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) were classified as treatment emergent AEs leading to study treatment discontinuation. For this Outcome Measure, AE up to week 52 are reported. 52 weeks
Primary Number of Participants With Treatment Emergent AEs Leading to Discontinuation From Study Treatment up to Week 156 - Cox Regression Model Adverse events leading to study treatment discontinuation starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) were classified as treatment emergent AEs leading to study treatment discontinuation 156 weeks
Secondary Number of Patients With at Least One Treatment Emergent AE by Primary System Organ Class up to Week 52 - Logistic Regression Model The number of patients per patient year of follow-up having a treatment emergent adverse event, categorized by system organ class. Treatment emergent adverse events are defined as an AEs starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) 52 weeks
Secondary Number of Patients With at Least One Treatment Emergent AE by Primary System Organ Class up to Week 156 - Logistic Regression Model The number of patients per patient year of follow-up having a treatment emergent adverse event, categorized by system organ class. Treatment emergent adverse events are defined as an AEs starting on or after the day of the first intake of study drug in this study and until the day of last intake of study drug +7 days (30 days in the case of a serious AE) 156 weeks
Secondary Number of Treatment Emergent Patient Deaths Due to an Asthma Exacerbation up to Week 52 The number of treatment emergent patient deaths due to an asthma exacerbation. Treatment emergent deaths are defined as deaths resulting from treatment emergent AEs. 52 weeks
Secondary Number of Treatment Emergent Patient Deaths Due to an Asthma Exacerbation up to Week 156 The number of treatment emergent patient deaths due to an asthma exacerbation. Treatment emergent deaths are defined as deaths resulting from treatment emergent AEs. 156 weeks
Secondary Rate of Treatment Emergent Severe Asthma Exacerbation Episodes Requiring Hospitalizations Per Person Year up to Week 52 Number of treatment emergent severe asthma exacerbation episodes requiring hospitalizations (any visit to the hospital requiring an overnight stay or an emergency room visit greater than 24 hours) per person year of follow-up. Treatment emergent severe asthma exacerbation episodes are defined as episodes occurring on or after the day of the first intake of study drug and until the day of last intake of study drug +7 days (30 days in the case of a serious AE).
Rate of exacerbations per person year = total number of exacerbations / total number of treatment years
52 weeks
Secondary Rate of Treatment Emergent Severe Asthma Exacerbation Episodes Requiring Hospitalizations Per Person Year up to Week 156 Number of treatment emergent severe asthma exacerbation episodes requiring hospitalizations (any visit to the hospital requiring an overnight stay or an emergency room visit greater than 24 hours) per person year of follow-up. Treatment emergent severe asthma exacerbation episodes are defined as episodes occurring on or after the day of the first intake of study drug and until the day of last intake of study drug +7 days (30 days in the case of a serious AE).
Rate of exacerbations per person year = total number of exacerbations / total number of treatment years
156 weeks
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device